- Zymeworks ( NASDAQ: ZYME ) said based on its current operational plans, it will have enough cash to fund R&D and operations through at least 2026 .
- The company said it ended 2022 with cash of $490M. In 2023, it expects cash burn of $90M-$120M.
- The biotech is also reorganizing its R&D team into two groups. One will focus on zanidatamab and the other on zanidatamab zovodotin and the rest of the pipeline.
- As part of the research reorganization, Zymeworks ( TSX: ZYME:CA ) said that Chief Medical Officer Neil Josephson is leaving the company.
- Zymeworks ( ZYME ) has signed commercialization agreements with Jazz Pharmaceuticals ( JAZZ ) and BeiGene ( BGNE ) for zanidatamab for HER2-expressing cancers.
- Since the end of December, Seeking Alpha's Quant Rating has viewed Zymeworks ( ZYME ) as a strong buy.
For further details see:
Zymeworks says cash runway will fund operations through 2026; CMO leaving biotech